Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Celebrex Long-Term Safety Study Planned

This article was originally published in The Pink Sheet Daily

Executive Summary

Pfizer will work with FDA to design a long-term safety study for Celebrex following the agency's decision to recommend a "black box" warning on the COX-2 inhibitor's increased risk for cardiovascular events

You may also be interested in...



Celebrex, NSAID Labeling Must Be Updated Within Three Months, FDA Says

FDA's labeling template calls for Pfizer's Celebrex and other prescription NSAIDs to add "black box" warnings on cardiovascular and gastrointestinal risks. FDA is also requiring a warning on skin reactions. The agency issues a medication guide for all NSAIDs.

Celebrex, NSAID Labeling Must Be Updated Within Three Months, FDA Says

FDA's labeling template calls for Pfizer's Celebrex and other prescription NSAIDs to add "black box" warnings on cardiovascular and gastrointestinal risks. FDA is also requiring a warning on skin reactions. The agency issues a medication guide for all NSAIDs.

Pfizer Sees Celebrex Script Growth After Bextra Withdrawal

Script data indicates patients are switching from Bextra to Celebrex, Pfizer says. In the last three weeks, Celebrex has led the NSAID market in new prescription growth.

Related Content

Topics

UsernamePublicRestriction

Register

PS062159

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel